Clinical Trial Update: Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the Galinpepimut-S WT-1 peptide vaccine in Malignant Pleural Mesothelioma after combined modality therapy. Results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Galinpepimut-S

Snippet

Sponsor: Sellas Life Sciences Group | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-09